A first-in-class PD-L1/B7-H3/VEGF tri-specific ADC achieves enhanced preclinical antitumor efficacy through direct cytotoxicity, immune checkpoint blockade and VEGF inhibition

ALK208 - Allink Biotherapeutics

Jiajia Pan; Pengfei Wang; Hongwang He; Mengfan Peng; Meng Cheng; Jie Zhang; Chengyi Ju; Jun Wang; Li Li; Hui Feng

Mar 18, 2026